Marketresearchnews

Monday 23 July 2018

Cell Isolation Market 2018 Share, Trend, Segmentation and Forecast to 2023

Market Scenario

The cell isolation market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the cell isolation market is expected to grow at a CAGR ~17.8 % during the forecast period of 2018–2023.

Cell isolation is the process of separating individual living cells from a cluster of tissue or cell suspension. It may be used for volume reduction of blood components, recovery of mononucleated cells from cord blood, the concentration of bone marrow, and other cell isolation applications.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6193

The market growth is mainly attributed to the increasing prevalence of cancer and infectious diseases and rising government funding for cell-based research. For instance, in 2015, the National Institutes of Health invested around 1,429 million USD for stem cells research. Moreover, technological advancements, growing research on personalized medicine and increasing demand for biopharmaceuticals is likely to contribute to the market growth during the forecast period. Despite the drivers, the high cost of cell isolation systems and complex cell behavior characteristics restrains the growth of the market.

Segmentation

The cell isolation market is segmented on the basis of product, cell type, technique, application, and end-user.

On the basis of the product, the market is classified as consumables and instruments. The consumables are further classified as reagents, kits, media, and sera, beads, disposables. The instruments are segmented into centrifuges, flow cytometers, magnetic-activated cell separation, and filtration system. The magnetic-activated cell separator system is further classified into manual magnetic-activated cell separator systems and automated magnetic-activated cell separator systems.

On the basis of cell type, the market is segmented into human cells and animal cells. The human cells are further segmented into differentiated cells and stem cells.

The cell isolation market on the basis of the technique is segmented as centrifugation-based cell isolation, surface marker-based cell isolation, and filtration-based cell isolation.

On the basis of the application, the market is segmented into biomolecule isolation, cancer research, stem cell research, tissue regeneration, in vitro diagnostics, and therapeutics.

On the basis of the end-user, the market is segmented as research laboratories and institutes, hospitals and diagnostic laboratories, cell banks, biotechnology and biopharmaceutical companies.

Geographically, cell isolation market has been segmented into America, Europe, Asia-Pacific, and the Middle East & Africa. The Americas cell isolation market is further segmented into North America, and South America. North America is further classified as the US and Canada.

The European cell isolation market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the Rest of Western Europe.

The Asia-Pacific cell isolation market is segmented into Japan, China, India, Republic of Korea, Australia, and the Rest of Asia-Pacific.

The Middle Eastern and African cell isolation market is segmented into the Middle East and Africa.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/6193

Regional Market Summary

The American region is expected to dominate the cell isolation market, owing to the existing well-established healthcare system, increasing prevalence of cancer cases, increasing government funding in research, and technological advancements. According to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancer had been diagnosed in the US Furthermore, the increasing cancer care expenditure in the United States is likely to drive the market growth. For instance, in 2017, the US Department of Health and Human Services estimated 147.3 billion USD national expenditures for cancer care.

Europe is anticipated to hold the second position in the cell isolation market. It is expected that the government support towards research & development expenditure and rising prevalence chronic diseases such as cancer is likely to drive the European cell isolation market. According to the Cancer Research UK, in 2012, 14.1 million cases of cancer were diagnosed all over the world, and 8.2 million died due to cancer. It also projected that the number of cancer patients is expected to reach 23.6 million in 2030.

The Asia-Pacific cell isolation market consists of countries namely China, Japan, Republic of Korea, India, and Australia. The market growth is mainly driven by rapidly expanding biopharmaceutical industries in the region and rising government funding in life sciences sector. Moreover, countries like India and China have established research institutes promoting cell-based research which contributes to the market growth.

The Middle East & Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.

Company Profiles

Beckman Coulter (Subsidiary of Danaher Corporation)
Becton, Dickinson, and Company
GE Healthcare (A Fully Owned Subsidiary of General Electric Company)
Merck KGaA
Thermo Fisher Scientific Inc.
Miltenyi Biotec
Pluriselect Life Science
Stemcell Technologies Inc.
Terumo Bct (A Subsidiary of Terumo Corporation)
Bio-Rad Laboratories, Inc.

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/6193

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Hyperglycemia Treatment Market- Global Industry Size, Share, Trends, Analysis and Forecast 2018 – 2023

Market Scenario

Hyperglycemia is an excess of glucose in the bloodstream, and is often associated with diabetes mellitus. It occurs when the body does not have enough insulin to control the sugar level or unable to produce the insulin. Furthermore, hyperglycemia if remains untreated may cause serious complications such as nerve damage or neuropathy, kidney damage, kidney failure, cardiovascular disease, eye disease, and skin problems such as bacterial and fungal infections. The major signs of hyperglycemia are polydipsia (a great thirst), polyuria (a need to urinate often), and a dry mouth.

Increasing prevalence of diabetes, and growing investment in biotechnology and pharmaceutical industries, and rising need for the better treatment methods drive the growth of the market.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4565

According to the WHO, the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Where as in 2015, 1.6 million deaths were caused due to diabetes. Another, 2.2 million deaths were attributed to high blood glucose level in 2012.

According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies across the globe. This is higher than the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

Moreover, increasing awareness about diabetes care and management, and advancing technology in medical devices are adding fuel to the growth of the market. Furthermore, increasing prevalence of obesity and consumption of unhealthy diet also drive the market growth.

However, availability of expensive treatment and poor reimbursement policy are some of the factors, which may slow the market growth during the forecast period.

The global hyperglycemia treatment market is expected to grow at a CAGR of 9.8 % during the forecast period 2017-2023.

Intended Audience

Pharmaceutical Companies
Medical Devices Companies
Research and Development (R&D) Companies
Government Research Institute
Academic Institutes and Universities

Segmentations

The global hyperglycemia treatment market is segmented on the basis of treatment, mode of administration, and end user.

On the basis of treatment, it is segmented into fluid replacement, electrolyte replacement, insulin therapy, and drugs. The drugs segment is further segmented into sulfonylureas, biguanides, thiazolidinediones, and others.

On the basis of mode of administration, it is segmented into topical, oral, and others.

On the basis of end user, the market is segmented into hospitals & clinics, retail pharmacy, and others

Regional Analysis

The Americas dominates the global hyperglycemia treatment market owing to well-developed technology, increasing patient with diabetes, increasing prevalence of neurological disorders, increasing patient population of kidney failure caused by severe hyperglycemia, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global hyperglycemia treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.

Asia Pacific is the fastest growing hyperglycemia treatment market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the hyperglycemia treatment in the region.

On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.

Key Players

Some of key the players in the market are Novo Nordisk A/S, Merck & Company Inc., Medtronic, Johnson & Johnson Services, Inc. , Teva Pharmaceuticals Ltd., Eli Lilly and Company, Sanofi S.A., Home Diagnostics, Bayer AG, Bristol-Myers Squibb., and Abbott.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4565

MAJOR TOC

1. Report Prologue

2. Market Introduction